Lymphoma

Cancer is an extremely complex disease. There are over 200 different types, some of which are considered common and others which are classified as rare cancers. But what exactly does it mean if a cancer is rare?  Usually, it means it…

Immunotherapy offers great promise in treating advanced cancers that do not respond to traditional treatments. To maximize the potential of the immune system via immunotherapy, however, clinicians must be able to…

Today, the FDA approved the use of nivolumab (Opdivo)―an anti-PD-1 antibody―to treat classical Hodgkin lymphoma. This is the first checkpoint immunotherapy approved for any type of lymphoma, and CRI is happy to know of…

Clinical trials are essential for turning cancer research breakthroughs into lifesaving treatments for patients, allowing doctors to learn which drugs work and which do not. The criteria used to evaluate patient…

The FDA announced today that it has approved the CAR T cell therapy Yescarta™ (axicabtagene ciloleucel, Kite/Gilead), for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or…

On May 1, 2018, the FDA approved a second CAR T cell immunotherapy—Novartis's Kymriah® (tisagenlecleucel)—for patients with relapsed or refractory large B cell lymphoma, a type of blood cancer. Like the first…

Jul 10, 2020In this episode, Dr. Catherine Diefenbach, Director of Hematology Translational Research and the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discusses clinical trials that address relapsed Hodgkin…